-+ 0.00%
-+ 0.00%
-+ 0.00%

OSE Immunotherapeutics hosts KOL webcast on lusvertikimab in ulcerative colitis

PUBT·08/28/2026 05:30:14
Listen to the news
OSE Immunotherapeutics hosts KOL webcast on lusvertikimab in ulcerative colitis
  • OSE Immunotherapeutics will host a KOL webcast on lusvertikimab on Sept. 2, 2026 at noon ET (6 p.m. CET).
  • Agenda includes IL-7R biology, Phase 2 CoTiKis ulcerative colitis results, future development plans in chronic pouchitis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSE Immunotherapeutics SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280130PRIMZONEFULLFEED1001259767) on August 28, 2026, and is solely responsible for the information contained therein.